TWENTY-SECOND AMENDMENT TO ELSEVIER LICENSE AGREEMENT

WHEREAS, the parties hereto have previously entered into an agreement dated 30 December 2003, as last amended 1 August 2007 (the "Prior Agreement") and wish to amend the Prior Agreement as set forth in this amendment ("Amendment").

NOW, THEREFORE, in consideration of the mutual promises and covenants set forth below, and for such other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree to amend the Prior Agreement as of the execution date below as set forth below and on Schedule 1.

Except as specifically amended hereby, all of the existing terms and conditions of the Prior Agreement are hereby ratified. Capitalized terms used herein that are not otherwise defined shall have the meanings ascribed to them in the Prior Agreement. To the extent any terms or conditions of the Prior Agreement conflict with or are inconsistent with this Amendment, the terms of this Amendment shall prevail.

IN WITNESS WHEREOF, the parties have executed this Amendment by their respective, duly authorized representatives as of 9 August 2007.

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
(Subscriber)

Name: 
Title: Director, Bus. Svcs.

ELSEVIER B.V.
(Licenser)

Name: 
Title: Managing Director, Sales

Contract Number: 4-7N4P8D

Version: 1 Aug 2005

AUG 27 2007
TWENTY-SECOND AMENDMENT TO
ELSEVIER LICENSE AGREEMENT
Schedule 1

The Licensed Products and Fees identified below are in addition to those identified in the Prior Agreement.

UNIVERSITY OF CALIFORNIA, IRVINE

<table>
<thead>
<tr>
<th>Licensed Products – publisher</th>
<th>Access</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>ScienceDirect® online – Elsevier B.V.</td>
<td>science direct.com</td>
<td>2007</td>
</tr>
<tr>
<td>Elsevier Book Series</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Methods in Cell Biology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOTAL FEES</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>